Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Am J Public Health ; 101(7): 1168-71, 2011 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-21653244

RESUMO

HIV partner services can effectively reach populations with high HIV prevalence. However, located and notified sex and needle-sharing partners of persons infected with HIV often fail to test. Field testing may increase the proportion of notified partners who test for HIV. In 2008, New York City's health department incorporated field testing into partner services. After the introduction of field testing, the proportion of notified partners who tested for HIV rose from 52% to 76% (P<.001). HIV prevalence fell slightly among notified partners who accepted testing (12% to 9%, P=.82), but we identified more than double the number of new positives (11 vs 25). All positive and 97% of negative results were received by the person tested.


Assuntos
Sorodiagnóstico da AIDS/estatística & dados numéricos , Busca de Comunicante/estatística & dados numéricos , Infecções por HIV/epidemiologia , Sorodiagnóstico da AIDS/métodos , Busca de Comunicante/economia , Infecções por HIV/diagnóstico , Custos de Cuidados de Saúde , Humanos , Cidade de Nova Iorque/epidemiologia
2.
HIV Clin Trials ; 4(1): 29-36, 2003.
Artigo em Inglês | MEDLINE | ID: mdl-12577194

RESUMO

PURPOSE: To evaluate nonfasting lipid levels in a large cohort of patients on three HAART regimens: efavirenz + zidovudine + lamivudine (EFV+ZDV+3TC), efavirenz + indinavir (EFV+IDV), and indinavir + zidovudine + lamivudine (IDV+ZDV+3TC). METHOD: Nonfasting lipid levels were analyzed from a large randomized multicenter treatment trial for HIV-infected patients initiating HAART. Treatment evaluations were carried out at prescribed intervals, and data were recorded and analyzed. Assessment was limited to high-density lipoprotein (HDL) and total cholesterol. RESULTS: The results demonstrate an increase in the total cholesterol, ranging from 23 to 57 mg/dL, in the three combinations of HAART therapy. The increase was most significant in the EFV+IDV arm where the effects appear to be additive. HDL cholesterol also increased in all three arms, but the greatest increase was in the two groups containing EFV. In all three arms, the HDL cholesterol increased significantly in women while increases in men were seen only in the EFV-containing arms. Men taking either IDV-containing regimen had a greater increase in total cholesterol, and therefore the total/HDL cholesterol ratio rose significantly. CONCLUSION: EFV and IDV independently elevate lipid levels. Alterations in the lipid levels may lead to increased cardiovascular risk in men, possibly mitigated by elevations in HDL cholesterol. In addition, changes in HDL cholesterol were significantly different between men and women.


Assuntos
Fármacos Anti-HIV/efeitos adversos , HDL-Colesterol/sangue , Colesterol/sangue , Infecções por HIV/tratamento farmacológico , Indinavir/efeitos adversos , Oxazinas/efeitos adversos , Adulto , Alcinos , Fármacos Anti-HIV/uso terapêutico , Terapia Antirretroviral de Alta Atividade , Benzoxazinas , Contagem de Linfócito CD4 , Ciclopropanos , Quimioterapia Combinada , Feminino , Infecções por HIV/sangue , Infecções por HIV/virologia , HIV-1/genética , HIV-1/isolamento & purificação , Humanos , Indinavir/uso terapêutico , Masculino , Oxazinas/uso terapêutico , RNA Viral/análise , Caracteres Sexuais , Fatores de Tempo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...